Navigation Links
The MDS foundation supports vidaza's recommendation for European approval

The Myelodysplastic Syndromes (MDS) Foundation supports the positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) recommending approval of VIDAZA (azacitidine) for specific types of MDS patients, including those with high-risk MDS, chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).

The CHMP positive opinion was based upon data from the AZA-001 trial, which found that VIDAZA nearly doubled the two-year survival rate for higher-risk MDS patients compared to conventional care regimens (CCR) with a mean survival of 24.5 months compared to 15 months for patients who received CCR.

"We are very encouraged by the CHMP's recommendation for marketing approval for VIDAZA," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "The MDS Foundation is committed to making sure that patients in need are aware of and have access to new treatments, like VIDAZA, that can help patients to live longer and allow them to have a better quality of life."

The AZA-001 trial also showed that, VIDAZA delays the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will progress to AML. The delay in progression is especially significant because patients with MDS are typically over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with AML is only approximately four percent.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells; red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.


Contact: Kathy Heptinstall
The Myelodysplastic Syndromes Foundation

Page: 1

Related biology news :

1. Meyskens honored with AACR-Prevent Cancer Foundation award
2. Parkinsons Disease Foundation announces award of $150,000
3. The Camille & Henry Dreyfus Foundation to host important symposium on chemistry and the environment
4. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
5. National Science Foundation grant expands UMCES oyster research
6. Dunn Foundation gives Rice $3M for collaborative research grants
7. National Science Foundation grants Clemson professors award to develop nanoprobes
8. Entertainment Software Association Foundation awards grant to FAS for immune attack
9. A major prize in the chemical sciences announced by the Camille and Henry Dreyfus Foundation
10. UT Knoxville wins 2 $3M National Science Foundation research and education grants
11. The MDS Foundation supports the FDAs decision to expand vidaza label to include survival data
Post Your Comments:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... 23, 2016 Andrew ... Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
Breaking Biology Technology: